Posted by Michael Wonder on 07 May 2024
Azurity Pharmaceuticals announces FDA approval of Myhibbin (mycophenolate mofetil oral suspension)
6 May 2024 - Azurity Pharmaceuticals announced today that the US FDA has approved Myhibbin, the only ready to use mycophenolate mofetil oral suspension.
It is expected that Myhibbin will become commercially available in pharmacies nationwide in Q2, 2024.
